XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Restructuring and Asset Impairment Charges (Tables)
9 Months Ended
Dec. 31, 2018
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
Restructuring charges for the Growth Initiative consisted of the following for the third quarter and first nine months of 2019:
 
Quarter Ended December 31, 2018
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
Medical-Surgical Solutions
 
Other
 
Corporate
 
Total
Severance and employee-related costs, net
$
1

 
$

 
$
9

 
$
31

 
$
41

Exit-related costs
1

 
5

 

 

 
6

Asset impairments and accelerated depreciation
2

 
1

 

 

 
3

Total
$
4

 
$
6

 
$
9

 
$
31

 
$
50

 
Nine Months Ended December 31, 2018
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
Medical-Surgical Solutions
 
Other
 
Corporate
 
Total
Severance and employee-related costs, net
$
4

 
$
10

 
$
16

 
$
31

 
$
61

Exit-related costs (1)
7

 
12

 
56

 

 
75

Asset impairments and accelerated depreciation
6

 
2

 
17

 

 
25

Total
$
17

 
$
24

 
$
89

 
$
31

 
$
161

(1)    Exit-related costs primarily include lease exit costs associated with closures of retail pharmacy stores within our Canadian business.
Schedule of Restructuring and Asset Impairment Charges
The following table summarizes the activity related to the restructuring liabilities associated with the Growth Initiative during the first nine months of 2019:
(In millions)
U.S. Pharmaceutical and Specialty Solutions
 
Medical-Surgical Solutions
 
Other
 
Corporate
 
Total
Balance, March 31, 2018
$

 
$

 
$

 
$

 
$

Net restructuring charges recognized
17

 
24

 
89

 
31

 
161

Non-cash charges
(6
)
 
(2
)
 
(17
)
 

 
(25
)
Cash payments
(7
)
 
(13
)
 
(36
)
 

 
(56
)
Balance, December 31, 2018 (1)
$
4

 
$
9

 
$
36

 
$
31

 
$
80


(1)
As of December 31, 2018, the total reserve balance was $80 million of which $49 million was recorded in other accrued liabilities and $31 million was recorded in other noncurrent liabilities.